SCHEMBL6610179

SCHEMBL6610179

CN(C)C=C1C(=O)Nc2ccc3ncccc3c21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
RET P07949 3/20 0.40
FLT3 P36888 1/20 0.40
MAPT P10636 7/20 0.40
NTRK1 P04629 3/20 0.40
NTRK3 Q16288 2/20 0.40
NTRK2 Q16620 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GSK3B P49841 2/20 0.40
HDAC6 Q9UBN7 1/20 0.40
AURKA O14965 1/20 0.40
ROCK2 O75116 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
CHEK2 O96017 1/20 0.40
INSR P06213 1/20 0.40
LCK P06239 1/20 0.40
CDK1 P06493 1/20 0.40
LYN P07948 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6610170 1.00 SMN1; SMN2 (0.48) SMN1; SMN2RETFLT3MAPTNTRK1
SCHEMBL3335156 0.77 MAPT (0.48) SMN1; SMN2MAPTMEN1KMT2ACHEK1
SCHEMBL5432754 0.76 ALDH1A1 (0.42) SMN1; SMN2RETFLT3MAPTNTRK1
SCHEMBL5432755 0.76 ALDH1A1 (0.42) SMN1; SMN2RETFLT3MAPTNTRK1
SCHEMBL6613240 0.76 LIPG (0.36) RETFLT3MAPTNTRK1NTRK3
SCHEMBL6613242 0.76 LIPG (0.36) RETFLT3MAPTNTRK1NTRK3
SCHEMBL5893585 0.75 SMN1; SMN2 (0.59) SMN1; SMN2RETMAPTNTRK1NTRK3
SCHEMBL5873941 0.75 SMN1; SMN2 (0.59) SMN1; SMN2RETMAPTNTRK1NTRK3
SCHEMBL6613736 0.74 TGM2 (0.32) SMN1; SMN2RETFLT3MAPTNTRK1
SCHEMBL6610327 0.74 CHEK1 (0.32) SMN1; SMN2RETFLT3MAPTNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313732-B1 OXINDOLE DERIVATIVES GLAXO GROUP LTD (GB) 2004-11-03 EP disclosed
US-6720332-B2 Oxindole derivatives SMITHKLINE BEECHAM CORPORATION 2004-04-13 US disclosed
US-20030195189-A1 Oxindole derivatives SMITHKLINE BEECHAM CORPORATION 2003-10-16 US disclosed
EP-1313732-A1 OXINDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-05-28 EP disclosed
WO-2002020524-A1 OXINDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195189-A1 Oxindole derivatives CDK4, CCNI, CCNO SMN1; SMN2 4091/4885RET 527/4885FLT3 938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.